Purpose of Review: This article describes clinical features of axonal sensorimotor polyneuropathies based on selected etiologies.
Recent Findings: Axonal sensorimotor polyneuropathies have been well described for some time. Recent advances include the assessment of the incidence of peripheral neuropathy in the elderly, the recognition of the limited influence of electrodiagnostic testing on the clinical management of uncomplicated axonal sensorimotor polyneuropathy, the development of guidelines for treatment of painful neuropathy, the identification of risk factors predisposing patients for chemotherapy-induced neuropathy, a report on the association of metabolic syndrome and idiopathic axonal sensorimotor neuropathy, and the availability of more cost-effective genetic testing for identifying inherited polyneuropathies.
Summary: Axonal sensorimotor polyneuropathies carry an extensive list of differential diagnoses. Diagnosis is based on detailed history, physical examination, recognition of associated neurologic and non-neurologic features, and appropriate testing. Disease-modifying treatments are lacking in many cases. Management focuses on modification of predisposing lifestyle and medical factors, rehabilitation, and pain relief.
Relationship Disclosure: Dr Li reports no disclosure.
Unlabeled Use of Products/Investigational Use Disclosure: Dr Li discusses the unlabeled/investigational use of tricyclic antidepressants, serotonin norepinephrine reuptake inhibitors, and voltage-gated calcium channel ligands for the treatment of painful polyneuropathy and the unlabeled/investigational use of diflunisal and tafamidis for familial amyloid polyneuropathy.
Address correspondence to Dr Yuebing Li, Cleveland Clinic, Neuromuscular Center Desk S90, 9500 Euclid Ave, Cleveland, OH 44195, email@example.com.